{"id":9125,"date":"2026-06-25T17:12:30","date_gmt":"2026-06-25T15:12:30","guid":{"rendered":"https:\/\/frosamariavivar.org\/global-call\/"},"modified":"2026-10-01T00:11:27","modified_gmt":"2026-09-30T22:11:27","slug":"global-call","status":"publish","type":"page","link":"https:\/\/frosamariavivar.org\/en\/global-call\/","title":{"rendered":"Global Call"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Global Call<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tA global call to identify and fund a preclinical research project focused on a pharmacological cure for Alzheimer's.<\/span>\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tSubmit Project<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\tCheck Requirements<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n
\n\t\t
\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

GLOBAL CALL<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Research that needs to go further<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tThe Global Call was created to open a channel of connection between the Rosa Maria Vivar Foundation and research teams working on the development of pharmacological strategies with curative potential for Alzheimer's.<\/span>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tThe objective is to fund a preclinical research project, with a clearly defined disease mechanism and a plausible path towards pharmacological intervention, through a two-phase evaluation process: Letter of Intent (LOI) and full proposal by invitation.\n<\/span>\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

The Call<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Areas of Interest<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tThe call is aimed at preclinical projects that propose a pharmacological intervention pathway with the potential to modify the course of the disease or contribute to a cure.<\/span>\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Disease Mechanisms and Therapeutic Targets<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tIdentification and validation of targets with a defined therapeutic pathway.<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Early Therapeutic Development<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tSmall molecules, biological therapies, or other modalities supported by a solid preclinical basis.<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Drug Repositioning<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tRepositioning proposals supported by robust evidence and clear mechanistic justification.<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\n<\/div>\n
\n\t\t
\n\t\t\t\t\t\"\"\/\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Who can submit a project<\/h3>\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tThe call is open to entities with their own legal personality, domicile or permanent establishment in Spain, that carry out R activities in national territory: universities, hospitals, public or private research centers and institutes, and biotechnology startups or companies with demonstrated R capacity.<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\tInternational cooperation through consortia is permitted, provided that a Spanish entity acts as the coordinating institution and recipient of the aid.
Each proposal must identify a principal investigator and a host institution responsible for the administrative and financial management of the project.<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Project Submission Form<\/h2>\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tTo rigorously evaluate each proposal, the form must collect scientific, technical, economic, and organizational information about the project.<\/span>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\n
\n\n
\n
\n\n
\n

1st Global Call for Alzheimer\u2019s Cure-Focused Research<\/h2>\n
\n

\n The Rosa Mar\u00eda Vivar Foundation launches this global call to fund one research project with a total budget of\n \u20ac160,000<\/strong> and a maximum duration of 24 months<\/strong>, aimed at advancing a cure-focused\n pharmacological approach to Alzheimer\u2019s disease. The call is open to R&D&I activities primarily based in Spain,\n including the possibility of international cooperation, is incompatible with other funding allocated to the same project,\n requires that all application materials be submitted in English, and limits indirect costs to a maximum of 15% of the total requested budget.\n <\/p>\n\n

\n This call is structured as a two-stage process consisting of a\n Letter of Intent (LOI)<\/strong> followed by a\n Full Proposal by invitation only.<\/strong>\n <\/p>\n\n

\n LOI submission period:<\/strong> June 15th \u2013 September 30th, 2026.\n <\/p>\n

\n \n
\n <\/div>\n\n

\n \n Download Full Call Document\n <\/a>\n <\/div>\n\n <\/div>\n <\/div>\n\n
\n \n

\n

\u26d4 The LOI submission period is currently closed.<\/strong>
\n Submissions are only accepted from June 15th to September 30th, 2026<\/strong>
<\/center>\n
\n
\n <\/div>\n\n <\/div>\n\n<\/div>\n\n